Tibet AIM Pharm. Inc.

Shenzhen Stock Exchange 002826.SZ

Tibet AIM Pharm. Inc. Goodwill for the year ending December 31, 2023: USD 2.35 M

Tibet AIM Pharm. Inc. Goodwill is USD 2.35 M for the year ending December 31, 2023, a -55.58% change year over year. Goodwill is the value attributed to intangible assets, such as brand reputation or customer relationships, acquired in a business combination.

Tibet AIM Pharm. Inc. Goodwill for the year ending December 31, 2022 was USD 5.29 M, a -7.92% change year over year.
Tibet AIM Pharm. Inc. Goodwill for the year ending December 31, 2021 was USD 5.74 M, a 388.68% change year over year.
Tibet AIM Pharm. Inc. Goodwill for the year ending December 31, 2020 was USD 1.17 M, a 6.69% change year over year.
Tibet AIM Pharm. Inc. Goodwill for the year ending December 31, 2019 was USD 1.10 M, a -1.24% change year over year.

Key data

Date	Goodwill	Total Assets	Current Liabilities	Total Non-Current Liabilities

Shenzhen Stock Exchange: 002826.SZ

Tibet AIM Pharm. Inc.

CEO	Ms. Zhou Min
IPO Date	Dec. 12, 2016
Location	China
Headquarters	Building C, Yingdu Building
Employees	439
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Clinical Trials Drugstores & Retail Pharmacies Personal Care

Description

Tibet AIM Pharm. Inc. engages in the research and development of medical products in China. The company's products include Miglitol tablets for diabetes; Gualoupi injection for coronary disease; Oxytocin injection for gynecology and obstetrics; NalMefene injection for various acute poisoning, such as alcohol, organic phosphor, CO, sedative-hypnotic, opioid substance, serious infection, shock, fainting, and brain; Carbetocin injections; and Hongjin Xiaojie tablets and Aceclofenac Enteric-Coated tablets, as well as for the treatment of antibiotic, antiallergic, and digestive system. Tibet AIM Pharm. Inc. was founded in 2003 and is headquartered in Beijing, China.

Key trends

Past 5 years